A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) containing the Inserted (I) domain variant of lymphocyte function-associated antigen-1 (LFA-1) which targets intercellular adhesion molecule-1 (ICAM-1 or CD54), and the co-stimulatory signaling domains of CD28, 4-1BB (CD137) and CD3zeta, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100 recognize and kill ICAM-1-expressing tumor cells. ICAM-1, normally expressed on leukocytes and endothelial cells, may be overexpressed in a variety of cancers. CAR T-cells AIC100 are also engineered to express somatostatin receptor subtype 2 (SSTR2), allowing the imaging of the CAR T-cells in patients.